AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (742.3 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies

Changyu Yao1,*, Shilun Wu1,*, Jian Kong1, Yiwen Sun2, Yannan Bai3, Ruhang Zhu1, Zhuxin Li1, Wenbing Sun1 ( ), Lemin Zheng4,5 ( )
Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China
Department of Pathology, Peking University People’s Hospital, Peking University, Beijing 100044, China
Department of Hepatobiliary Pancreatic Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou 350001, China
The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, Key Laboratory of Molecular Cardiovascular Sciences of Ministry of Education, Health Sciences Center, Peking University, Beijing 100083, China
Beijing Tiantan Hospital, China National Clinical Research Center of Neurological Diseases, Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 100050, China

*These authors contributed equally to this work.

Show Author Information

Abstract

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-associated death worldwide. Angiogenesis, the process of formation of new blood vessels, is required for cancer cells to obtain nutrients and oxygen. HCC is a typical hypervascular solid tumor with an aberrant vascular network and angiogenesis that contribute to its growth, progression, invasion, and metastasis. Current anti-angiogenic therapies target mainly tyrosine kinases, vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR), and are considered effective strategies for HCC, particularly advanced HCC. However, because the survival benefits conferred by these anti-angiogenic therapies are modest, new anti-angiogenic targets must be identified. Several recent studies have determined the underlying molecular mechanisms, including pro-angiogenic factors secreted by HCC cells, the tumor microenvironment, and cancer stem cells. In this review, we summarize the roles of pro-angiogenic factors; the involvement of endothelial cells, hepatic stellate cells, tumor-associated macrophages, and tumor-associated neutrophils present in the tumor microenvironment; and the regulatory influence of cancer stem cells on angiogenesis in HCC. Furthermore, we discuss some of the clinically approved anti-angiogenic therapies and potential novel therapeutic targets for angiogenesis in HCC. A better understanding of the mechanisms underlying angiogenesis may lead to the development of more optimized anti-angiogenic treatment modalities for HCC.

Keywords

Angiogenesistumor microenvironmenthepatocellular carcinomaanti-angiogenic therapypro-angiogenic factors

References

1

Wang C, Cao Y, Yang C, Bernards R, Qin W. Exploring liver cancer biology through functional genetic screens. Nat Rev Gastroenterol Hepatol. 2021; 18: 690-704.
Crossref Google Scholar
2

Jamshidi-Parsian A, Griffin RJ, Kore RA, Todorova VK, Makhoul I. Tumor-endothelial cell interaction in an experimental model of human hepatocellular carcinoma. Exp Cell Res. 2018; 372: 16-24.
Crossref Google Scholar
3

Yan T, Yu L, Zhang N, Peng C, Su G, Jing Y, et al. The advanced development of molecular targeted therapy for hepatocellular carcinoma. Cancer Biol Med. 2022; 19: 802-17.
Crossref Google Scholar
4

Ribatti D, Annese T, Ruggieri S, Tamma R, Crivellato E. Limitations of anti-angiogenic treatment of tumors. Transl Oncol. 2019; 12: 981-6.
Crossref Google Scholar
5

Cheng W, Cheng Z, Weng L, Xing D, Zhang M. Asparagus polysaccharide inhibits the hypoxia-induced migration, invasion and angiogenesis of hepatocellular carcinoma cells partly through regulating HIF1α/VEGF expression via MAPK and PI3K signaling pathway. J Cancer. 2021; 12: 3920-9.
Crossref Google Scholar
6

Xiong XX, Qiu XY, Hu DX, Chen XQ. Advances in hypoxiamediated mechanisms in hepatocellular carcinoma. Mol Pharmacol. 2017; 92: 246-55.
Crossref Google Scholar
7

Feng J, Li J, Wu L, Yu Q, Ji J, Wu J, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020; 39: 126.
Crossref Google Scholar
8

Shah AA, Kamal MA, Akhtar S. Tumor angiogenesis and VEGFR- 2: mechanism, pathways and current biological therapeutic interventions. Curr Drug Metab. 2021; 22: 50-9.
Crossref Google Scholar
9

Muppala S. Growth factor-induced angiogenesis in hepatocellular carcinoma. Crit Rev Oncog. 2021; 26: 61-8.
Crossref Google Scholar
10

Elaimy AL, Mercurio AM. Convergence of VEGF and YAP/TAZ signaling: Implications for angiogenesis and cancer biology. Sci Signal. 2018; 11: 1165.
Crossref Google Scholar
11

Pulkkinen HH, Kiema M, Lappalainen JP, Toropainen A, Beter M, Tirronen A, et al. BMP6/TAZ-Hippo signaling modulates angiogenesis and endothelial cell response to VEGF. Angiogenesis. 2021; 24: 129-44.
Crossref Google Scholar
12

Aguilar-Cazares D, Chavez-Dominguez R, Carlos-Reyes A, Lopez-Camarillo C, Hernadez de la Cruz ON, Lopez-Gonzalez JS. Contribution of angiogenesis to inflammation and cancer. Front Oncol. 2019; 9: 1399.
Crossref Google Scholar
13

Lacin S, Yalcin S. The prognostic value of circulating VEGF-A level in patients with hepatocellular cancer. Technol Cancer Res Treat. 2020; 19: 1533033820971677.
Crossref Google Scholar
14

Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019; 176: 1248-64.
Crossref Google Scholar
15

Chen H, Nio K, Tang H, Yamashita T, Okada H, Li Y, et al. BMP9-ID1 signaling activates HIF-1α and VEGFA expression to promote tumor angiogenesis in hepatocellular carcinoma. Int J Mol Sci. 2022; 23: 1475.
Crossref Google Scholar
16

Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011; 8: 292-301.
Crossref Google Scholar
17

Demoulin JB, Essaghir A. PDGF receptor signaling networks in normal and cancer cells. Cytokine Growth Factor Rev. 2014; 25: 273-83.
Crossref Google Scholar
18

Chen B, Liu J, Wang X, Shen Q, Li C, Dai C. Co-expression of PDGF-B and VEGFR-3 strongly correlates with poor prognosis in hepatocellular carcinoma patients after hepatectomy. Clin Res Hepatol Gastroenterol. 2018; 42: 126-33.
Crossref Google Scholar
19

Papadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target. Mol Aspects Med. 2018; 62: 75-88.
Crossref Google Scholar
20

Zou X, Tang XY, Qu ZY, Sun ZW, Ji CF, Li YJ, et al. Targeting the PDGF/PDGFR signaling pathway for cancer therapy: a review. Int J Biol Macromol. 2022; 202: 539-57.
Crossref Google Scholar
21

Tsioumpekou M, Cunha SI, Ma H, Åhgren A, Cedervall J, Olsson AK, et al. Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression. Theranostics. 2020; 10: 1122-35.
Crossref Google Scholar
22

Olsen RS, Dimberg J, Geffers R, Wågsäter D. Possible role and therapeutic target of PDGF-D signalling in colorectal cancer. Cancer Invest. 2019; 37: 99-112.
Crossref Google Scholar
23

Li L, Ji Y, Chen YC, Zhen ZJ. MiR-325-3p mediate the CXCL17/ CXCR8 axis to regulate angiogenesis in hepatocellular carcinoma. Cytokine. 2021; 141: 155436.
Crossref Google Scholar
24

Chen CY, Wu SM, Lin YH, Chi HC, Lin SL, Yeh CT, et al. Induction of nuclear protein-1 by thyroid hormone enhances plateletderived growth factor A mediated angiogenesis in liver cancer. Theranostics. 2019; 9: 2361-79.
Crossref Google Scholar
25

Presta M, Chiodelli P, Giacomini A, Rusnati M, Ronca R. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Pharmacol Ther. 2017; 179: 171-87.
Crossref Google Scholar
26

Szybowska P, Kostas M, Wesche J, Wiedlocha A, Haugsten EM. Cancer mutations in FGFR2 prevent a negative feedback loop mediated by the ERK1/2 pathway. Cells. 2019; 8: 518.
Crossref Google Scholar
27

Wang Y, Liu D, Zhang T, Xia L. FGF/FGFR signaling in hepatocellular carcinoma: from carcinogenesis to recent therapeutic intervention. Cancers (Basel). 2021; 13: 1360.
Crossref Google Scholar
28

Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res. 2011; 17: 6130-9.
Crossref Google Scholar
29

Pallotta MT, Nickel W. FGF2 and IL-1β - explorers of unconventional secretory pathways at a glance. J Cell Sci. 2020; 133: 250449.
Crossref Google Scholar
30

Morse MA, Sun W, Kim R, He AR, Abada PB, Mynderse M, et al. The role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res. 2019; 25: 912-20.
Crossref Google Scholar
31

Wang L, Park H, Chhim S, Ding Y, Jiang W, Queen C, et al. A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. Mol Cancer Ther. 2012; 11: 864-72.
Crossref Google Scholar
32

Margioula-Siarkou G, Margioula-Siarkou C, Petousis S, Margaritis K, Vavoulidis E, Gullo G, et al. The role of endoglin and its soluble form in pathogenesis of preeclampsia. Mol Cell Biochem. 2022; 477: 479-91.
Crossref Google Scholar
33

Ungogo MA. Targeting Smad-mediated TGFβ pathway in coronary artery bypass graft. J Cardiovasc Pharmacol Ther. 2021; 26: 119-30.
Crossref Google Scholar
34

Alsamman M, Sterzer V, Meurer SK, Sahin H, Schaeper U, Kuscuoglu D, et al. Endoglin in human liver disease and murine models of liver fibrosis - a protective factor against liver fibrosis. Liver Int. 2018; 38: 858-67.
Crossref Google Scholar
35

Jeng KS, Sheen IS, Lin SS, Leu CM, Chang CF. The role of endoglin in hepatocellular carcinoma. Int J Mol Sci. 2021; 22: 3208.
Crossref Google Scholar
36

Kasprzak A, Adamek A. Role of endoglin (CD105) in the progression of hepatocellular carcinoma and anti-angiogenic therapy. Int J Mol Sci. 2018; 19: 3887.
Crossref Google Scholar
37

Li L, Zhong L, Tang C, Gan L, Mo T, Na J, et al. CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target. Clin Transl Oncol. 2022; 24: 1447-58.
Crossref Google Scholar
38

Schoonderwoerd MJA, Goumans MTH, Hawinkels LJAC. Endoglin: beyond the endothelium. Biomolecules. 2020; 10: 289.
Crossref Google Scholar
39

Pomeraniec L, Hector-Greene M, Ehrlich M, Blobe GC, Henis YI. Regulation of TGF-β receptor hetero-oligomerization and signaling by endoglin. Mol Biol Cell. 2015; 26: 3117-27.
Crossref Google Scholar
40

Hong JM, Hu YD, Chai XQ, Tang CL. Role of activin receptor-like kinase 1 in vascular development and cerebrovascular diseases. Neural Regen Res. 2020; 15: 1807-13.
Crossref Google Scholar
41

Yang Y, Guan Q, Guo L, Han C. The prognostic correlation between CD105 expression level in tumor tissue and peripheral blood and sunitinib administration in advanced hepatocellular carcinoma. Cancer Biol Ther. 2018; 19: 1006-14.
Crossref Google Scholar
42

Zhao W, Yang L, Chen X, Qian H, Zhang S, Chen Y, et al. Phenotypic and functional characterization of tumor-derived endothelial cells isolated from primary human hepatocellular carcinoma. Hepatol Res. 2018; 48: 1149-62.
Crossref Google Scholar
43

Benetti A, Berenzi A, Gambarotti M, Garrafa E, Gelati M, Dessy E, et al. Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium. Cancer Res. 2008; 68: 8626-34.
Crossref Google Scholar
44

Li Y, Zhai Z, Liu D, Zhong X, Meng X, Yang Q, et al. CD105 promotes hepatocarcinoma cell invasion and metastasis through VEGF. Tumour Biol. 2015; 36: 737-45.
Crossref Google Scholar
45

Yao Y, Pan Y, Chen J, Sun X, Qiu Y, Ding Y. Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF. Ann Clin Lab Sci. 2007; 37: 39-48.
Google Scholar
46

Xiong YQ, Sun HC, Zhang W, Zhu XD, Zhuang PY, Zhang JB, et al. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res. 2009; 15: 4838-46.
Crossref Google Scholar
47

Duffy AG, Ma C, Ulahannan SV, Rahma OE, Makarova-Rusher O, Cao L, et al. Phase I and preliminary phase Ⅱ study of TRC105 in combination with sorafenib in hepatocellular carcinoma. Clin Cancer Res. 2017; 23: 4633-41.
Crossref Google Scholar
48

Bupathi M, Kaseb A, Janku F. Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives. Onco Targets Ther. 2014; 7: 1927-32.
Crossref Google Scholar
49

Vanderborght B, Lefere S, Vlierberghe HV, Devisscher L. The angiopoietin/Tie2 pathway in hepatocellular carcinoma. Cells. 2020; 9: 2382.
Crossref Google Scholar
50

Akwii RG, Sajib MS, Zahra FT, Mikelis CM. Role of angiopoietin-2 in vascular physiology and pathophysiology. Cells. 2019; 8: 471.
Crossref Google Scholar
51

Choi GH, Jang ES, Kim JW, Jeong SH. Prognostic role of plasma level of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor in hepatocellular carcinoma. World J Gastroenterol. 2021; 27: 4453-67.
Crossref Google Scholar
52

Ao J, Chiba T, Kanzaki H, Kanayama K, Shibata S, Kurosugi A, et al. Serum angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma. J Cancer. 2021; 12: 2694-701.
Crossref Google Scholar
53

Roškar L, Roškar I, Rižner TL, Smrkolj Š. Diagnostic and therapeutic values of angiogenic factors in endometrial cancer. Biomolecules. 2021; 12: 7.
Crossref Google Scholar
54

Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, et al. Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut. 2005; 54: 1768-75.
Crossref Google Scholar
55

Wang Q, Lash GE. Angiopoietin 2 in placentation and tumor biology: the yin and yang of vascular biology. Placenta. 2017; 56: 73-8.
Crossref Google Scholar
56

Wang F, Dong X, Xiu P, Zhong J, Wei H, Xu Z, et al. T7 peptide inhibits angiogenesis via downregulation of angiopoietin-2 and autophagy. Oncol Rep. 2015; 33: 675-84.
Crossref Google Scholar
57

Tanaka S, Wands JR, Arii S. Induction of angiopoietin-2 gene expression by COX-2: a novel role for COX-2 inhibitors during hepatocarcinogenesis. J Hepatol. 2006; 44: 233-5.
Crossref Google Scholar
58

Terlikowska KM, Dobrzycka B, Terlikowski R, Sienkiewicz A, Kinalski M, Terlikowski SJ. Clinical value of selected markers of angiogenesis, inflammation, insulin resistance and obesity in type 1 endometrial cancer. BMC Cancer. 2020; 20: 921.
Crossref Google Scholar
59

Modzelewska P, Chludzińska S, Lewko J, Reszeć J. The influence of leptin on the process of carcinogenesis. Contemp Oncol (Pozn). 2019; 23: 63-8.
Crossref Google Scholar
60

Huang H, Zhang J, Ling F, Huang Y, Yang M, Zhang Y, et al. Leptin receptor (LEPR) promotes proliferation, migration, and invasion and inhibits apoptosis in hepatocellular carcinoma by regulating ANXA7. Cancer Cell Int. 2021; 21: 4.
Crossref Google Scholar
61

Ho Y, Wang SH, Chen YR, Li ZL, Chin YT, Yang YSH, et al. Leptinderived peptides block leptin-induced proliferation by reducing expression of pro-inflammatory genes in hepatocellular carcinoma cells. Food Chem Toxicol. 2019; 133: 110808.
Crossref Google Scholar
62

Ribatti D, Belloni AS, Nico B, Di Comite M, Crivellato E, Vacca A. Leptin-leptin receptor are involved in angiogenesis in human hepatocellular carcinoma. Peptides. 2008; 29: 1596-602.
Crossref Google Scholar
63

Lin TC, Hsiao M. Leptin and cancer: updated functional roles in carcinogenesis, therapeutic niches, and developments. Int J Mol Sci. 2021; 22: 2870.
Crossref Google Scholar
64

Zabeau L, Wauman J, Dam J, Van Lint S, Burg E, De Geest J, et al. A novel leptin receptor antagonist uncouples leptin’s metabolic and immune functions. Cell Mol Life Sci. 2019; 76: 1201-14.
Crossref Google Scholar
65

Fiedor E, Gregoraszczuk EL. Superactive human leptin antagonist (SHLA), triple Lan1 and quadruple Lan2 leptin mutein as a promising treatment for human folliculoma. Cancer Chemother Pharmacol. 2017; 80: 815-27.
Crossref Google Scholar
66

Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, et al. The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res. 2020; 39: 204.
Crossref Google Scholar
67

Liu Y, Han ZP, Zhang SS, Jing YY, Bu XX, Wang CY, et al. Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer. J Biol Chem. 2011; 286: 25007-15.
Crossref Google Scholar
68

Mu HQ, He YH, Wang SB, Yang S, Wang YJ, Nan CJ, et al. MiR-130b/TNF-α/NF-κB/VEGFA loop inhibits prostate cancer angiogenesis. Clin Transl Oncol. 2020; 22: 111-21.
Crossref Google Scholar
69

Tsai CN, Yu SC, Lee CW, Pang JS, Wu CH, Lin SE, et al. SOX4 activates CXCL12 in hepatocellular carcinoma cells to modulate endothelial cell migration and angiogenesis in vivo. Oncogene. 2020; 39: 4695-710.
Crossref Google Scholar
70

Li Y, Turpin CP, Wang S. Role of thrombospondin 1 in liver diseases. Hepatol Res. 2017; 47: 186-93.
Crossref Google Scholar
71

Yang HD, Kim HS, Kim SY, Na MJ, Yang G, Eun JW, et al. HDAC6 suppresses let-7i-5p to elicit TSP1/CD47-mediated antitumorigenesis and phagocytosis of hepatocellular carcinoma. Hepatology. 2019; 70: 1262-79.
Crossref Google Scholar
72

Poluzzi C, Iozzo RV, Schaefer L. Endostatin and endorepellin: a common route of action for similar angiostatic cancer avengers. Adv Drug Deliv Rev. 2016; 97: 156-73.
Crossref Google Scholar
73

Ji Y, Fan H, Yang M, Bai C, Yang W, Wang Z. Synergistic effect of baculovirus-mediated endostatin and angiostatin combined with gemcitabine in hepatocellular carcinoma. Biol Pharm Bull. 2022; 45: 309-15.
Crossref Google Scholar
74

Kapoor A, Chen CG, Iozzo RV. Endorepellin evokes an angiostatic stress signaling cascade in endothelial cells. J Biol Chem. 2020; 295: 6344-56.
Crossref Google Scholar
75

Wang K, Qiu X, Zhao Y, Wang H, Chen L. The Wnt/β- catenin signaling pathway in the tumor microenvironment of hepatocellular carcinoma. Cancer Biol Med. 2021; 19: 305-18.
Crossref Google Scholar
76

Yang W, Li Z, Qin R, Wang X, An H, Wang Y, et al. YY1 promotes endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma by transcriptionally activating VEGFA. Front Oncol. 2019; 9: 1187.
Crossref Google Scholar
77

Meng J, Liu Y, Han J, Tan Q, Chen S, Qiao K, et al. Hsp90β promoted endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma. Mol Cancer. 2017; 16: 72.
Crossref Google Scholar
78

Wang W, Wu F, Fang F, Tao Y, Yang L. RhoC is essential for angiogenesis induced by hepatocellular carcinoma cells via regulation of endothelial cell organization. Cancer Sci. 2008; 99: 2012-8.
Crossref Google Scholar
79

Dong ZR, Sun D, Yang YF, Zhou W, Wu R, Wang XW, et al. TMPRSS4 drives angiogenesis in hepatocellular carcinoma by promoting HB-EGF expression and proteolytic cleavage. Hepatology. 2020; 72: 923-39.
Crossref Google Scholar
80

Sun XT, Yuan XW, Zhu HT, Deng ZM, Yu DC, Zhou X, et al. Endothelial precursor cells promote angiogenesis in hepatocellular carcinoma. World J Gastroenterol. 2012; 18: 4925-33.
Crossref Google Scholar
81

Ruan Q, Wang H, Burke LJ, Bridle KR, Li X, Zhao CX, et al. Therapeutic modulators of hepatic stellate cells for hepatocellular carcinoma. Int J Cancer. 2020; 147: 1519-27.
Crossref Google Scholar
82

Lin JZ, Meng LL, Li YZ, Chen SX, Xu JL, Tang YJ, et al. Importance of activated hepatic stellate cells and angiopoietin-1 in the pathogenesis of hepatocellular carcinoma. Mol Med Rep. 2016; 14: 1721-5.
Crossref Google Scholar
83

Lin N, Meng L, Lin J, Chen S, Zhang P, Chen Q, et al. Activated hepatic stellate cells promote angiogenesis in hepatocellular carcinoma by secreting angiopoietin-1. J Cell Biochem. 2020; 121: 1441-51.
Crossref Google Scholar
84

Zhu B, Lin N, Zhang M, Zhu Y, Cheng H, Chen S, et al. Activated hepatic stellate cells promote angiogenesis via interleukin-8 in hepatocellular carcinoma. J Transl Med. 2015; 13: 365.
Crossref Google Scholar
85

Li ZQ, Wu WR, Zhao C, Zhao C, Zhang XL, Yang Z, et al. CCN1/ Cyr61 enhances the function of hepatic stellate cells in promoting the progression of hepatocellular carcinoma. Int J Mol Med. 2018; 41: 1518-28.
Crossref Google Scholar
86

Mußbach F, Ungefroren H, Günther B, Katenkamp K, Henklein P, Westermann M, et al. Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells - evidence for a role in hepatocellular carcinoma growth in vivo. Mol Cancer. 2016; 15: 54.
Crossref Google Scholar
87

Lu Y, Lin N, Chen Z, Xu R. Hypoxia-induced secretion of plateletderived growth factor-BB by hepatocellular carcinoma cells increases activated hepatic stellate cell proliferation, migration and expression of vascular endothelial growth factor-A. Mol Med Rep. 2015; 11: 691-7.
Crossref Google Scholar
88

Li W, Miao S, Miao M, Li R, Cao X, Zhang K, et al. Hedgehog signaling activation in hepatic stellate cells promotes angiogenesis and vascular mimicry in hepatocellular carcinoma. Cancer Invest. 2016; 34: 424-30.
Crossref Google Scholar
89

Li Z, Wang F, Li Y, Wang X, Lu Q, Wang D, et al. Combined anti-hepatocellular carcinoma therapy inhibit drug-resistance and metastasis via targeting “substance P-hepatic stellate cellshepatocellular carcinoma” axis. Biomaterials. 2021; 276: 121003.
Crossref Google Scholar
90

Peng H, Zhu E, Zhang Y. Advances of cancer-associated fibroblasts in liver cancer. Biomark Res. 2022; 10: 59.
Crossref Google Scholar
91

Khan GJ, Sun L, Khan S, Yuan S, Nongyue H. Versatility of cancer associated fibroblasts: commendable targets for anti-tumor therapy. Curr Drug Targets. 2018; 19: 1573-88.
Crossref Google Scholar
92

Biffi G, Tuveson DA. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021; 101: 147-76.
Crossref Google Scholar
93

Wang SS, Tang XT, Lin M, Yuan J, Peng YJ, Yin X, et al. Perivenous stellate cells are the main source of myofibroblasts and cancerassociated fibroblasts formed after chronic liver injuries. Hepatology. 2021; 74: 1578-94.
Crossref Google Scholar
94

Zhou Y, Ren H, Dai B, Li J, Shang L, Huang J, et al. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancerassociated fibroblasts. J Exp Clin Cancer Res. 2018; 37: 324.
Crossref Google Scholar
95

Huang B, Huang M, Li Q. Cancer-associated fibroblasts promote angiogenesis of hepatocellular carcinoma by VEGF-mediated EZH2/VASH1 pathway. Technol Cancer Res Treat. 2019; 18: 1533033819879905.
Crossref Google Scholar
96

Liu Z, Chen M, Zhao R, Huang Y, Liu F, Li B, et al. CAFinduced placental growth factor facilitates neoangiogenesis in hepatocellular carcinoma. Acta Biochim Biophys Sin (Shanghai). 2020; 52: 18-25.
Crossref Google Scholar
97

Chiavarina B, Ronca R, Otaka Y, Sutton RB, Rezzola S, Yokobori T, et al. Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma. Oncogene. 2022; 41: 1410-20.
Crossref Google Scholar
98

de Oliveira S, Houseright RA, Graves AL, Golenberg N, Korte BG, Miskolci V, et al. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. J Hepatol. 2019; 70: 710-21.
Crossref Google Scholar
99

Ye Y, Xu Y, Lai Y, He W, Li Y, Wang R, et al. Long non-coding RNA cox-2 prevents immune evasion and metastasis of hepatocellular carcinoma by altering M1/M2 macrophage polarization. J Cell Biochem. 2018; 119: 2951-63.
Crossref Google Scholar
100

Pu J, Li W, Wang A, Zhang Y, Qin Z, Xu Z, et al. Long non-coding RNA HOMER3-AS1 drives hepatocellular carcinoma progression via modulating the behaviors of both tumor cells and macrophages. Cell Death Dis. 2021; 12: 1103.
Crossref Google Scholar
101

Hou ZH, Xu XW, Fu XY, Zhou LD, Liu SP, Tan DM. Long non-coding RNA MALAT1 promotes angiogenesis and immunosuppressive properties of HCC cells by sponging miR-140. Am J Physiol Cell Physiol. 2020; 318: 649-63.
Crossref Google Scholar
102

Goswami KK, Bose A, Baral R. Macrophages in tumor: an inflammatory perspective. Clin Immunol. 2021; 232: 108875.
Crossref Google Scholar
103

Yan C, Huo X, Wang S, Feng Y, Gong Z. Stimulation of hepatocarcinogenesis by neutrophils upon induction of oncogenic kras expression in transgenic zebrafish. J Hepatol. 2015; 63: 420-8.
Crossref Google Scholar
104

Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB, et al. Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology. 2016; 150: 1646-58.
Crossref Google Scholar
105

Yan C, Yang Q, Gong Z. Tumor-associated neutrophils and macrophages promote gender disparity in hepatocellular carcinoma in zebrafish. Cancer Res. 2017; 77: 1395-407.
Crossref Google Scholar
106

Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020; 20: 485-503.
Crossref Google Scholar
107

Mossenta M, Busato D, Baboci L, Cintio FD, Toffoli G, Bo MD. New insight into therapies targeting angiogenesis in hepatocellular carcinoma. Cancers (Basel). 2019; 11: 1086.
Crossref Google Scholar
108

Yang X, Zhao J, Duan S, Hou X, Li X, Hu Z, et al. Enhanced cytotoxic T lymphocytes recruitment targeting tumor vasculatures by endoglin aptamer and IP-10 plasmid presenting liposome-based nanocarriers. Theranostics. 2019; 9: 4066-83.
Crossref Google Scholar
109

Duan S, Song M, He J, Zhou N, Zhou S, Zhao J, et al. Folate-modified chitosan nanoparticles coated interferon-inducible protein-10 gene enhance cytotoxic T lymphocytes’ responses to hepatocellular carcinoma. J Biomed Nanotechnol. 2016; 12: 700-9.
Crossref Google Scholar
110

Yao H, Liu N, Lin MC, Zheng J. Positive feedback loop between cancer stem cells and angiogenesis in hepatocellular carcinoma. Cancer Lett. 2016; 379: 213-9.
Crossref Google Scholar
111

Lee TK, Guan XY, Ma S. Cancer stem cells in hepatocellular carcinoma-from origin to clinical implications. Nat Rev Gastroenterol Hepatol. 2022; 19: 26-44.
Crossref Google Scholar
112

Zeng SS, Yamashita T, Kondo M, Nio K, Hayashi T, Hara Y, et al. The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma. J Hepatol. 2014; 60: 127-34.
Crossref Google Scholar
113

Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010; 59: 953-62.
Crossref Google Scholar
114

Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, et al. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/ CXCL1 signaling. Hepatology. 2012; 55: 807-20.
Crossref Google Scholar
115

Conigliaro A, Costa V, Lo Dico A, Saieva L, Buccheri S, Dieli F, et al. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. Mol Cancer. 2015; 14: 155.
Crossref Google Scholar
116

Suda T, Yamashita T, Sunagozaka H, Okada H, Nio K, Sakai Y, et al. Dickkopf-1 promotes angiogenesis and is a biomarker for hepatic stem cell-like hepatocellular carcinoma. Int J Mol Sci. 2022; 23: 2801.
Crossref Google Scholar
117

Cheng CC, Chao WT, Shih JH, Lai YS, Hsu YH, Liu YH. Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma. Cancer Chemother Pharmacol. 2021; 88: 143-53.
Crossref Google Scholar
118

Zheng N, Zhang S, Wu W, Zhang N, Wang J. Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma. Pharmacol Res. 2021; 166: 105507.
Crossref Google Scholar
119

Zhao X, Sun B, Liu T, Shao B, Sun R, Zhu D, et al. Long noncoding RNA n339260 promotes vasculogenic mimicry and cancer stem cell development in hepatocellular carcinoma. Cancer Sci. 2018; 109: 3197-208.
Crossref Google Scholar
120

Ou H, Chen Z, Xiang L, Fang Y, Xu Y, Liu Q, et al. Frizzled 2-induced epithelial-mesenchymal transition correlates with vasculogenic mimicry, stemness, and Hippo signaling in hepatocellular carcinoma. Cancer Sci. 2019; 110: 1169-82.
Crossref Google Scholar
121

Akce M, El-Rayes BF, Bekaii-Saab TS. Frontline therapy for advanced hepatocellular carcinoma: an update. Therap Adv Gastroenterol. 2022; 15: 17562848221086126.
Crossref Google Scholar
122

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-90.
Crossref Google Scholar
123

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
Crossref Google Scholar
124

Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer. 2020; 1874: 188391.
Crossref Google Scholar
125

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391: 1163-73.
Crossref Google Scholar
126

Guan H, Wang C, Zhao Z, Han S. Cost-effectiveness of donafenib as first-line treatment of unresectable hepatocellular carcinoma in China. Adv Ther. 2022; 39: 3334-46.
Crossref Google Scholar
127

Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase Ⅱ-Ⅲ trial. J Clin Oncol. 2021; 39: 3002-11.
Crossref Google Scholar
128

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389: 56-66.
Crossref Google Scholar
129

Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020; 5: 146.
Crossref Google Scholar
130

Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018; 379: 54-63.
Crossref Google Scholar
131

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20: 282-96.
Crossref Google Scholar
132

Niu M, Yi M, Li N, Wu K, Wu K. Advances of targeted therapy for hepatocellular carcinoma. Front Oncol. 2021; 11: 719896.
Crossref Google Scholar
133

Zhang XH, Cao MQ, Li XX, Zhang T. Apatinib as an alternative therapy for advanced hepatocellular carcinoma. World J Hepatol. 2020; 12: 766-74.
Crossref Google Scholar
134

Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2021; 6: 559-68.
Crossref Google Scholar
135

Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019; 18(1): 60.
Crossref Google Scholar
136

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020; 382: 1894-95.
Crossref Google Scholar
137

Luo XY, Wu KM, He XX. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. J Exp Clin Cancer Res. 2021; 40: 172.
Crossref Google Scholar
138

He M, Hu J, Fang T, Tang W, Lv B, Yang B, et al. Protein convertase subtilisin/Kexin type 9 inhibits hepatocellular carcinoma growth by interacting with GSTP1 and suppressing the JNK signaling pathway. Cancer Biol Med. 2021; 19: 90-103.
Crossref Google Scholar
139

Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020; 5: 87.
Crossref Google Scholar
Cancer Biology & Medicine
Volume 20 Issue 1,
January 2023
Pages 25-43
DOI: 10.20892/j.issn.2095-3941.2022.0449
Cite this article:
Yao C, Wu S, Kong J, et al. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies. Cancer Biology & Medicine, 2023, 20(1): 25-43. https://doi.org/10.20892/j.issn.2095-3941.2022.0449

291

Views

9

Downloads

39

Crossref

36

Web of Science

37

Scopus

Altmetrics
Received: 27 July 2022
Accepted: 19 October 2022
Published: 12 January 2023
©2023 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License
Return